Mines D`or Orbec Inc

Despite numerous challenges, 2seventy bio, formerly part of bluebird bio, remains focused on achieving profitability with its CAR T therapy Abecma. The company has undergone layoffs, pipeline reorganizations, and faced competition and FDA safety warnings. CEO Chip Baird predicts profitability next year, with potential growth strategies including acquisitions or licensing deals. The company's culture and resilience among its employees have been key to its survival.

Pfizer is withdrawing Oxbryta, a sickle cell disease treatment, from all markets due to risks of vaso-occlusive crises and deaths. The decision follows an imbalance in fatal events observed in clinical trials, prompting regulatory reviews. Pfizer advises patients to consult their physicians for alternative treatments.

Pfizer withdraws Oxbryta, its sickle cell disease therapy, from worldwide markets due to higher risk of deaths and complications, leaving patients and doctors seeking alternatives.

Editas Medicine focuses on sickle cell disease, intellectual property monetization, and in vivo pipeline advancement. Its lead candidate, reni-cel, shows promising results in treating SCD and Thalassemia. Editas faces competition from established players but aims to leverage its strong patent estate and unique up-regulation techniques. Data updates from the RUBY trial in 2024 could significantly impact its market performance.

Pfizer withdraws sickle cell drug Oxbryta from global market due to safety concerns, leaving patients and advocates scrambling. The decision follows EMA review highlighting increased vaso-occlusive crisis cases. Pfizer pauses ongoing clinical trials and shuts down expanded access programs. The FDA advises against prescribing Oxbryta and recommends alternative treatments.

Pfizer's withdrawal of Oxbryta due to death risk may accelerate trials of rivals like Agios' mitapivat and Fulcrum's pociredir. Oxbryta's suspension leaves mild-moderate patients reliant on hydroxyurea. Gene therapies Lyfgenia and Casgevy target severe cases. Pfizer's stock dips amid broader challenges.

Pfizer withdraws Oxbryta® due to 16 patient deaths in clinical trials, citing imbalance in vaso-occlusive crises and fatal events. The European Medicines Agency reports 18 deaths in two Phase III trials, with 16 linked to the drug. Pfizer halts all clinical trials and expanded access programs globally.

Pfizer withdraws Oxbryta from worldwide markets due to clinical data indicating the drug's risks no longer outweigh its benefits. The decision follows an imbalance in vaso-occlusive crises and fatal events observed in trials. Pfizer will halt clinical trials while reviewing data and advises patients to consult their physicians for alternative treatments.

Pfizer withdraws Oxbryta, its sickle cell disease treatment, from global markets due to increased risks of vaso-occlusive crises and fatal events. The decision follows recent FDA approvals of two gene therapies for SCD, Casgevy and Lyfgenia, which offer potential cures but come with high costs.